LifeStance Announces Q3 Revenue of $363.8 Million, Exceeding Consensus Estimate of $355.03 Million
Record Growth: LifeStance reported a record-breaking quarter with 17% organic visit growth and an increase in clinician numbers to approximately 8,000.
Financial Performance: The company achieved a positive net income of $1 million and an Adjusted EBITDA of $40 million, marking new highs as a public entity.
Operational Efficiency: Improved operating leverage in general and administrative expenses has allowed LifeStance to raise its full-year Adjusted EBITDA guidance while expanding margins.
Future Outlook: The strong results from this quarter provide momentum as LifeStance prepares for the fourth quarter and the upcoming year.
Trade with 70% Backtested Accuracy
Analyst Views on LFST
About LFST
About the author
Biohaven Ltd's Depression Drug Trial Fails to Meet Primary Endpoint, Shares Plunge 14.3%
- Drug Trial Failure: Biohaven Ltd announced that its depression drug BHV-7000 failed to significantly reduce depressive symptoms in a six-week clinical trial, causing shares to plummet 14.3% to $9.27 in pre-market trading, reflecting a substantial decline in market confidence regarding its R&D capabilities.
- Severe Market Reaction: The news of the trial's failure triggered panic among investors, leading to a rapid decline in Biohaven's stock price during pre-market trading, indicating the high sensitivity of the biopharmaceutical sector to clinical outcomes, which may impact the company's future financing and R&D plans.
- Increased Competitive Pressure: With Biohaven's drug trial failure, market attention shifts to other competitors, particularly in the depression treatment space, potentially leading investors to reassess the market outlook and investment value of related companies.
- Wider Industry Implications: Biohaven's failure could have a ripple effect across the biopharmaceutical industry, particularly in terms of R&D investments and clinical trial designs, prompting other companies to more cautiously evaluate their drug development strategies.
SeaStar Medical Announces 1-for-10 Reverse Split, Shares Drop 9.5%
- Reverse Split Impact: SeaStar Medical's announcement of a 1-for-10 reverse split led to a 9.5% drop in pre-market trading, bringing the share price down to $0.21, reflecting market concerns about the company's future prospects.
- Market Reaction: Following the reverse split news, SeaStar's stock price quickly declined, indicating a lack of investor confidence in the company's financial health, which could affect its ability to raise capital and its market image.
- Other Stock Movements: Coincheck Group NV and Ascent Solar Technologies also saw declines in pre-market trading, dropping 11% and 7.6% respectively, indicating a broader bearish sentiment in the market that may influence investor risk appetite.
- Industry Trends: In light of the market's reaction to the reverse split, SeaStar Medical may need to reassess its capital structure and future strategy to restore investor confidence and improve stock performance.
BMO Capital Begins Coverage of LifeStance Health Group with Outperform Rating and Sets Price Target at $8
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform provides essential tools and information that traders use daily to succeed in the markets.
Almost 70% of Americans Experience Pressure to Seem Happier Than They Actually Are This Holiday Season
Survey Findings: A LifeStance Health survey reveals that 57% of Americans find the holiday season stressful, with Millennials and Gen Z feeling the most pressure to attend gatherings and appear happy.
Generational Trends: 64% of respondents would prefer to skip some holiday gatherings, with 34% of Millennials and 33% of Gen Z wanting to avoid most or all events.
Feelings of Loneliness: 51% of respondents report feeling lonely during the holidays, even in the company of loved ones, while 69% feel pressure to project happiness.
Post-Holiday Sentiments: After the holiday season, 59% of respondents typically feel positive or refreshed, while 17% experience sadness or disappointment.
Top Analysts Recommend 3 Best Stocks to Purchase Now, 9/29/2025
Top Stock Picks: Analysts have identified three stocks—Lifestance Health Group, Glaukos, and Klaviyo, Inc.—as Strong Buys, each with significant upside potential based on recent ratings from top Wall Street analysts.
Lifestance Health Group: This Arizona-based mental health service provider has a 12-month price target suggesting a 64.84% upside, with all four top analysts recommending a Buy.
Glaukos: A medical technology company focused on eye treatments, Glaukos has a potential growth of 60.13% according to analysts, with four out of five top analysts giving it a Buy rating.
Klaviyo, Inc.: This Boston-based tech firm has a 12-month price target indicating a 46.83% growth potential, with all nine top analysts recently rating it as a Buy.
Sarah Personette Appointed to LifeStance Board of Directors
Leadership Change at LifeStance Health: Sarah Personette has been appointed to the board of directors at LifeStance Health, while William Miller will step down after five years of service.
Experience of New Board Member: Personette brings over 20 years of experience in customer experience and media, having held significant roles at companies like Puck, X (formerly Twitter), Refinery29, and Facebook.
Commitment to Patient-Centered Care: LifeStance Health emphasizes its dedication to improving patient experiences, aligning with Personette's expertise in understanding consumer behavior.
Company Overview: LifeStance Health, founded in 2017, is a major provider of outpatient mental health care across the U.S., employing around 7,700 professionals and operating over 550 centers.
Biohaven Ltd's Depression Drug Trial Fails to Meet Primary Endpoint, Shares Plunge 14.3%
- Drug Trial Failure: Biohaven Ltd announced that its depression drug BHV-7000 failed to significantly reduce depressive symptoms in a six-week clinical trial, causing shares to plummet 14.3% to $9.27 in pre-market trading, reflecting a substantial decline in market confidence regarding its R&D capabilities.
- Severe Market Reaction: The news of the trial's failure triggered panic among investors, leading to a rapid decline in Biohaven's stock price during pre-market trading, indicating the high sensitivity of the biopharmaceutical sector to clinical outcomes, which may impact the company's future financing and R&D plans.
- Increased Competitive Pressure: With Biohaven's drug trial failure, market attention shifts to other competitors, particularly in the depression treatment space, potentially leading investors to reassess the market outlook and investment value of related companies.
- Wider Industry Implications: Biohaven's failure could have a ripple effect across the biopharmaceutical industry, particularly in terms of R&D investments and clinical trial designs, prompting other companies to more cautiously evaluate their drug development strategies.
SeaStar Medical Announces 1-for-10 Reverse Split, Shares Drop 9.5%
- Reverse Split Impact: SeaStar Medical's announcement of a 1-for-10 reverse split led to a 9.5% drop in pre-market trading, bringing the share price down to $0.21, reflecting market concerns about the company's future prospects.
- Market Reaction: Following the reverse split news, SeaStar's stock price quickly declined, indicating a lack of investor confidence in the company's financial health, which could affect its ability to raise capital and its market image.
- Other Stock Movements: Coincheck Group NV and Ascent Solar Technologies also saw declines in pre-market trading, dropping 11% and 7.6% respectively, indicating a broader bearish sentiment in the market that may influence investor risk appetite.
- Industry Trends: In light of the market's reaction to the reverse split, SeaStar Medical may need to reassess its capital structure and future strategy to restore investor confidence and improve stock performance.
BMO Capital Begins Coverage of LifeStance Health Group with Outperform Rating and Sets Price Target at $8
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform provides essential tools and information that traders use daily to succeed in the markets.
Almost 70% of Americans Experience Pressure to Seem Happier Than They Actually Are This Holiday Season
Survey Findings: A LifeStance Health survey reveals that 57% of Americans find the holiday season stressful, with Millennials and Gen Z feeling the most pressure to attend gatherings and appear happy.
Generational Trends: 64% of respondents would prefer to skip some holiday gatherings, with 34% of Millennials and 33% of Gen Z wanting to avoid most or all events.
Feelings of Loneliness: 51% of respondents report feeling lonely during the holidays, even in the company of loved ones, while 69% feel pressure to project happiness.
Post-Holiday Sentiments: After the holiday season, 59% of respondents typically feel positive or refreshed, while 17% experience sadness or disappointment.
Top Analysts Recommend 3 Best Stocks to Purchase Now, 9/29/2025
Top Stock Picks: Analysts have identified three stocks—Lifestance Health Group, Glaukos, and Klaviyo, Inc.—as Strong Buys, each with significant upside potential based on recent ratings from top Wall Street analysts.
Lifestance Health Group: This Arizona-based mental health service provider has a 12-month price target suggesting a 64.84% upside, with all four top analysts recommending a Buy.
Glaukos: A medical technology company focused on eye treatments, Glaukos has a potential growth of 60.13% according to analysts, with four out of five top analysts giving it a Buy rating.
Klaviyo, Inc.: This Boston-based tech firm has a 12-month price target indicating a 46.83% growth potential, with all nine top analysts recently rating it as a Buy.
Sarah Personette Appointed to LifeStance Board of Directors
Leadership Change at LifeStance Health: Sarah Personette has been appointed to the board of directors at LifeStance Health, while William Miller will step down after five years of service.
Experience of New Board Member: Personette brings over 20 years of experience in customer experience and media, having held significant roles at companies like Puck, X (formerly Twitter), Refinery29, and Facebook.
Commitment to Patient-Centered Care: LifeStance Health emphasizes its dedication to improving patient experiences, aligning with Personette's expertise in understanding consumer behavior.
Company Overview: LifeStance Health, founded in 2017, is a major provider of outpatient mental health care across the U.S., employing around 7,700 professionals and operating over 550 centers.
